Johnson & Johnson (JNJ) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Total Assets Chart for Johnson & Johnson
Johnson & Johnson (JNJ) total assets for FY2025 were USD 199.2B, a 10.6% change from FY2024. Johnson & Johnson's total assets grew from USD 5.1B in 1985 to USD 199.2B in 2025 (3809.8% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 2.6%, 10-year CAGR of 4.1%, 20-year CAGR of 6.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $635.56B
- Implied Share Price
- $263.73
- Enterprise Value
- $677.00B
- Revenue (TTM)
- $97.93B
- EBITDA
- $34.87B
- Profit Margin
- 21.48%
- Trailing P/E
- 30.81
- Forward P/E
- 21.01
- Price/Book (MRQ)
- 7.63
- Price/Sales (TTM)
- 6.49
- EV/EBITDA
- 19.94
- EV/Revenue
- 6.91
- Dividend Yield
- 2.00%
- Book Value
- $35.28
- Free Cash Flow (FY2025)
- $19.70B
- Free Cash Flow Yield
- 3.10%
Snapshot as of 13th October 2026 — not point-in-time controlled, may lag the live market by a few days.